PL2294086T3 - Środki przeciwzapalne - Google Patents
Środki przeciwzapalneInfo
- Publication number
- PL2294086T3 PL2294086T3 PL09757582T PL09757582T PL2294086T3 PL 2294086 T3 PL2294086 T3 PL 2294086T3 PL 09757582 T PL09757582 T PL 09757582T PL 09757582 T PL09757582 T PL 09757582T PL 2294086 T3 PL2294086 T3 PL 2294086T3
- Authority
- PL
- Poland
- Prior art keywords
- inflammatory agents
- inflammatory
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08157547 | 2008-06-04 | ||
EP08171920 | 2008-12-17 | ||
EP09155484 | 2009-03-18 | ||
EP09757582.3A EP2294086B1 (en) | 2008-06-04 | 2009-06-04 | Anti-inflammatory agents |
PCT/EP2009/056862 WO2009147201A2 (en) | 2008-06-04 | 2009-06-04 | Anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2294086T3 true PL2294086T3 (pl) | 2018-02-28 |
Family
ID=40943595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09757582T PL2294086T3 (pl) | 2008-06-04 | 2009-06-04 | Środki przeciwzapalne |
Country Status (16)
Country | Link |
---|---|
US (2) | US9718877B2 (pl) |
EP (1) | EP2294086B1 (pl) |
JP (1) | JP5528436B2 (pl) |
KR (1) | KR101752499B1 (pl) |
CN (1) | CN102056944A (pl) |
AU (1) | AU2009253923B2 (pl) |
BR (1) | BRPI0913945A2 (pl) |
CA (1) | CA2726511C (pl) |
DK (1) | DK2294086T3 (pl) |
EA (1) | EA023302B9 (pl) |
ES (1) | ES2652127T3 (pl) |
IL (1) | IL209741A0 (pl) |
NO (1) | NO2294086T3 (pl) |
PL (1) | PL2294086T3 (pl) |
WO (1) | WO2009147201A2 (pl) |
ZA (1) | ZA201008727B (pl) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056944A (zh) | 2008-06-04 | 2011-05-11 | 莫蒂克斯特私人有限公司 | 抗炎症药剂 |
EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
US20110262505A1 (en) | 2010-04-22 | 2011-10-27 | Gina Athwal | Seaweed-derived cosmetic compositions |
EP2402368A1 (en) | 2010-07-02 | 2012-01-04 | Toscana Biomarkers S.r.l. | Histone citrullinated peptides and uses thereof |
EP2527841A1 (en) * | 2011-05-25 | 2012-11-28 | Toscana Biomarkers S.r.l. | Methods for the diagnosis of rheumatoid arthritis |
WO2013105721A1 (ko) * | 2012-01-13 | 2013-07-18 | 가톨릭대학교 산학협력단 | 류마티스 관절염 진단 키트 |
KR101458100B1 (ko) | 2012-01-13 | 2014-11-05 | 가톨릭대학교 산학협력단 | 류마티스 관절염 진단 키트 |
EP2804876A4 (en) * | 2012-01-19 | 2016-02-24 | Vilara Ab | NEW ANTIBODIES |
FR3007411B1 (fr) * | 2013-06-21 | 2015-07-03 | Agronomique Inst Nat Rech | Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations |
US20160159922A1 (en) * | 2013-07-24 | 2016-06-09 | Vilara Ab | Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis |
DK3140323T3 (en) * | 2014-05-05 | 2018-07-23 | Novio Th B V | METHOD OF SEROLOGICAL DIAGNOSTICATION OF RHEUMATOID ARTHRITIS. |
AU2015359262B2 (en) | 2014-12-11 | 2021-02-04 | Citryll B.V. | Method for the treatment of idiopathic pulmonary fibrosis |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
WO2016179326A1 (en) | 2015-05-05 | 2016-11-10 | The Regents Of The University Of California | H3.3 ctl peptides and uses thereof |
WO2019101863A1 (en) | 2017-11-22 | 2019-05-31 | Vacara Ab | Antibodies to citrullinated proteins |
CU24508B1 (es) * | 2017-12-29 | 2021-04-07 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición farmacéutica que comprende péptido tipo apl |
JP7084057B2 (ja) * | 2018-06-20 | 2022-06-14 | 株式会社ファーマフーズ | 新規抗pad2抗体 |
KR20210056355A (ko) | 2018-08-21 | 2021-05-18 | 씨트릴 비.브이. | 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체 |
EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
EP4333981A1 (en) | 2021-05-04 | 2024-03-13 | Citryll B.V. | Inhibition of eosinophilic traps |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
NL1004539C2 (nl) * | 1996-11-15 | 1998-05-20 | Stichting Tech Wetenschapp | Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen. |
JP2002512939A (ja) * | 1997-11-28 | 2002-05-08 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド |
CA2391356A1 (en) | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
US8198401B2 (en) * | 2003-03-07 | 2012-06-12 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis |
GB0721605D0 (en) | 2007-11-02 | 2007-12-12 | Cancer Rec Tech Ltd | Prostrate cancer susceptibility screening |
CN102056944A (zh) | 2008-06-04 | 2011-05-11 | 莫蒂克斯特私人有限公司 | 抗炎症药剂 |
-
2009
- 2009-06-04 CN CN2009801210911A patent/CN102056944A/zh active Pending
- 2009-06-04 EP EP09757582.3A patent/EP2294086B1/en active Active
- 2009-06-04 WO PCT/EP2009/056862 patent/WO2009147201A2/en active Application Filing
- 2009-06-04 JP JP2011512123A patent/JP5528436B2/ja active Active
- 2009-06-04 DK DK09757582.3T patent/DK2294086T3/en active
- 2009-06-04 NO NO09757582A patent/NO2294086T3/no unknown
- 2009-06-04 CA CA2726511A patent/CA2726511C/en active Active
- 2009-06-04 PL PL09757582T patent/PL2294086T3/pl unknown
- 2009-06-04 KR KR1020107029828A patent/KR101752499B1/ko active IP Right Grant
- 2009-06-04 EA EA201001865A patent/EA023302B9/ru not_active IP Right Cessation
- 2009-06-04 BR BRPI0913945A patent/BRPI0913945A2/pt not_active Application Discontinuation
- 2009-06-04 AU AU2009253923A patent/AU2009253923B2/en active Active
- 2009-06-04 ES ES09757582.3T patent/ES2652127T3/es active Active
- 2009-06-04 US US12/737,075 patent/US9718877B2/en active Active
-
2010
- 2010-12-02 IL IL209741A patent/IL209741A0/en unknown
- 2010-12-03 ZA ZA2010/08727A patent/ZA201008727B/en unknown
-
2017
- 2017-06-22 US US15/630,020 patent/US10703822B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170298146A1 (en) | 2017-10-19 |
AU2009253923A1 (en) | 2009-12-10 |
CA2726511C (en) | 2018-07-10 |
AU2009253923B2 (en) | 2014-02-13 |
EA201001865A1 (ru) | 2011-06-30 |
ES2652127T3 (es) | 2018-01-31 |
JP2011523555A (ja) | 2011-08-18 |
KR20110015035A (ko) | 2011-02-14 |
BRPI0913945A2 (pt) | 2016-09-27 |
EA023302B1 (ru) | 2016-05-31 |
CA2726511A1 (en) | 2009-12-10 |
IL209741A0 (en) | 2011-02-28 |
US20110243945A1 (en) | 2011-10-06 |
US10703822B2 (en) | 2020-07-07 |
WO2009147201A2 (en) | 2009-12-10 |
EA023302B9 (ru) | 2016-10-31 |
KR101752499B1 (ko) | 2017-06-29 |
JP5528436B2 (ja) | 2014-06-25 |
WO2009147201A3 (en) | 2010-01-28 |
CN102056944A (zh) | 2011-05-11 |
US9718877B2 (en) | 2017-08-01 |
EP2294086A2 (en) | 2011-03-16 |
ZA201008727B (en) | 2012-01-25 |
NO2294086T3 (pl) | 2018-02-10 |
EP2294086B1 (en) | 2017-09-13 |
DK2294086T3 (en) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20182200T1 (hr) | Nova protuupalna sredstva | |
IL211147A0 (en) | 1h-benzimidazole-5-carboxamides as anti-inflammatory agents | |
IL230542B (en) | Anti-inflammatory factors | |
ZA201008727B (en) | Anti-inflammatory agents | |
PL2403852T3 (pl) | 2-aminobenzoimidazolo-5-karboksyamidy jako środki przeciwzapalne | |
PL2918172T3 (pl) | Połączenia środków kontroli biologicznej i fungicydów | |
EP2132086A4 (en) | SPORTBOARD STRUCTURES | |
GB0809344D0 (en) | Palringo local | |
ZA200906100B (en) | Sportsboard structures | |
GB0814728D0 (en) | New combination | |
GB0823140D0 (en) | New combination | |
GB0811100D0 (en) | New combination | |
GB0814729D0 (en) | New combination | |
GB0901480D0 (en) | Contrast agents | |
GB0823141D0 (en) | New combination | |
GB0810062D0 (en) | Threapeutic agents | |
AU4098P (en) | NPW2 Dianella tasmanica | |
GB0808644D0 (en) | Places | |
AU2009904787A0 (en) | Anti-inflammatory agents | |
GB0723750D0 (en) | Therapeutuic agents | |
GB0808161D0 (en) | Flatrad & anglerad | |
GB0810963D0 (en) | Mud-monster & tail-safe | |
GB0710085D0 (en) | I | |
HU0800039V0 (en) | Construction set | |
GB0805969D0 (en) | Clevertee pro |